PHAR
Price
$13.14Alerts
Change
-$0.07 (-0.53%)
Updated
Nov 11 closing price
Capitalization
869.86M
127 days until earnings call
Intraday BUY SELL Signals
TRDA
Price
$5.44Alerts
Change
+$0.19 (+3.62%)
Updated
Nov 11 closing price
Capitalization
190.4M
126 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PHAR vs TRDA

PHAR vs TRDA Comparison Chart in %
View a ticker or compare two or three
VS
PHAR vs. TRDA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAR is a Buy and TRDA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PHAR with price predictions
Nov 10, 2026

Momentum Indicator for PHAR turns positive, indicating new upward trend

PHAR saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 111 similar instances where the indicator turned positive. In 93 of the 111 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PHAR just turned positive on October 20, 2026. Looking at past instances where PHAR's MACD turned positive, the stock continued to rise in 48 of 61 cases over the following month. The odds of a continued upward trend are 79%.

PHAR moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PHAR crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.

Following a +7.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in 168 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

PHAR broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PHAR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PHAR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.216) is normal, around the industry mean (3.498). PHAR has a moderately high P/E Ratio (88.107) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.080) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.168) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for TRDA with price predictions
Nov 10, 2026

TRDA in +16.14% Uptrend, growing for three consecutive days on November 02, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TRDA advanced for three days, in 263 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TRDA's RSI Indicator exited the oversold zone, 15 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on TRDA as a result. In 74 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for TRDA just turned positive on October 28, 2026. Looking at past instances where TRDA's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.

TRDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for TRDA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.816) is normal, around the industry mean (3.498). P/E Ratio (-1.235) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (61.350) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. TRDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
PHAR: Fundamental Ratings
PHAR
OUTLOOK RATING
1..100
31
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
PROFIT vs RISK RATING
1..100
75
SMR RATING
1..100
86
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHARTRDA
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 10 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 29 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (PHAR: $13.22 vs. TRDA: $5.25)
Brand notoriety: PHAR and TRDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAR: 22% vs. TRDA: 184%
Market capitalization -- PHAR: $869.86M vs. TRDA: $190.4M
PHAR [@Biotechnology] is valued at $869.86M. TRDA’s [@Biotechnology] market capitalization is $190.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAR’s FA Score shows that 0 FA rating(s) are green while TRDA’s FA Score has 1 green FA rating(s).

  • PHAR’s FA Score: 0 green, 5 red.
  • TRDA’s FA Score: 1 green, 4 red.
According to our system of comparison, TRDA is a better buy in the long-term than PHAR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAR’s TA Score shows that 5 TA indicator(s) are bullish while TRDA’s TA Score has 5 bullish TA indicator(s).

  • PHAR’s TA Score: 5 bullish, 5 bearish.
  • TRDA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TRDA is a better buy in the short-term than PHAR.

Price Growth

PHAR (@Biotechnology) experienced а +2.24% price change this week, while TRDA (@Biotechnology) price change was +11.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.

Reported Earning Dates

PHAR is expected to report earnings on Mar 18, 2027.

TRDA is expected to report earnings on Mar 17, 2027.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

PHAR and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAR has been loosely correlated with TRDA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAR jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
+0.46%
TRDA - PHAR
44%
Loosely correlated
+11.94%
ENGN - PHAR
43%
Loosely correlated
-5.65%
LKFT - PHAR
36%
Loosely correlated
-0.33%
INSM - PHAR
34%
Loosely correlated
+2.92%
LGND - PHAR
33%
Loosely correlated
+0.00%
More

TRDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRDA has been closely correlated with ENGN. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TRDA jumps, then ENGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRDA
1D Price
Change %
TRDA100%
+11.94%
ENGN - TRDA
76%
Closely correlated
-5.65%
ARQT - TRDA
44%
Loosely correlated
+4.52%
PHAR - TRDA
43%
Loosely correlated
+0.46%
INSM - TRDA
42%
Loosely correlated
+2.92%
KRRO - TRDA
42%
Loosely correlated
+5.15%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TANH30.5611.01
+56.32%
Tantech Holdings Ltd.
VKTX28.66-0.33
-1.14%
Viking Therapeutics
RGLD274.57-8.09
-2.86%
Royal Gold
FINV2.88-0.10
-3.36%
FinVolution Group
CAN0.16-0.04
-19.15%
Canaan